JG-2016

JG-2016 is an inhibitor of histone acetyltransferase 1 (HAT1, IC50 = 14.8 µM). It is selective for HAT1 over lysine acetyltransferase 2A (KAT2A/GCN5) and p300/CBP-associated factor (PCAF), for which it has no activity, KAT5, KAT6B, and KAT7 (IC50s = >100, >100, and 84.82 µM, respectively), CREB-binding protein (CBP), and p300 (IC50s = 90.41 and 74.25 µM, respectively). JG-2016 (20 µM) reduces acetylation of histone H4 lysine 5 (H4K5) and H4K12 in hTert-HME1 mammary epithelial cells. It reduces the growth of HCC1806 triple-negative breast cancer and A549 lung cancer cells (EC50s = 10.4 and 1.9 µM, respectively). JG-2016 reduces intratumoral H4K12 acetylation in an A549 mouse xenograft model in a dose-dependent manner. It also reduces tumor growth in an A549 mouse xenograft model when administered at doses of 50 and 100 mg/kg once every three days.Formal Name: 7-chloro-8-ethyl-10-[2-(2-methylpropoxy)ethyl]-benzo[g]pteridine-2,4(3H,10H)-dione. CAS Number: 2887480-87-5. Molecular Formula: C18H21ClN4O3. Formula Weight: 376.8. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Sparingly soluble: 1-10 mg/ml, Ethanol: Slightly soluble: 0.1-1 mg/ml. SMILES: O=C1N=C2C(C(N1)=O)=NC3=C(N2CCOCC(C)C)C=C(CC)C(Cl)=C3. InChi Code: InChI=1S/C18H21ClN4O3/c1-4-11-7-14-13(8-12(11)19)20-15-16(21-18(25)22-17(15)24)23(14)5-6-26-9-10(2)3/h7-8,10H,4-6,9H2,1-3H3,(H,22,24,25). InChi Key: IOHJEWFKBRNJIO-UHFFFAOYSA-N.